Table 2.
Radioembolization technique, dose, treatment response, and toxicity. CR: complete response. LSF: lung shunt fracture. NA: data not available. PR: partial response. rRHA: replaced right hepatic artery. SD: stable disease.
| Pt# | Delivery Method, Dose (gy) | LSF (%) | 1 mo Toxicity | 3 mo Toxicity | Best Target Lesion Response | Target Lesion Progression | Non-target Lesion Progression and Reason | Overall Survival |
|---|---|---|---|---|---|---|---|---|
| 1 | 1st session: Right lobar delivery for segment 7 lesion (153 Gy) in remnant right lobe; 2nd session: split segmental delivery for left lobe lesions ×3 (190 Gy and 117 Gy) 3rd session segmental deliveries to progressed segment 2/3/4 lesions (443/409/156 Gy) |
1st and 2nd sessions: 1.7% 3rd session: 3.1% |
G1 nausea, vomiting during 1st, 2nd and 3rd session. | G1 fatigue after 2nd and 3rd session. | 1st session segment 7: CR 2nd session: PR ×3. 3rd session re-treatment of segment ⅔ lesions: CR. |
1st session lesion: negative for 14 months 2nd session lesions ×3: recurrence at 5 month 3rd session: Not reported because this treatment was retreatment. |
New liver tumors in 2 months after 1st session. | 17 months, alive, scheduled for living donor liver transplant |
| 2 | Left hepatic artery to segment 2 and 3 (152 Gy) | 15.4% | G1 fever, thrombocytopenia leukopenia | G1 diarrhea, thrombocytopenia. G2 leukopenia, albuminemia. | CR | Negative for 12 months | Negative for 12 months | 12 months, alive. Pending tumor board discussion. |
| 3 | 1st session: segment 6 (142Gy) and right lobar (92Gy); 2nd: right hepatic artery (251Gy); 3rd: right hepatic artery (121) |
1st: 3.3%; 2nd: 8.0% 3rd: 8.3%; |
G1 fatigue after 1st session; G1 nausea after 3rd session G1 ALP after 3rd session. |
G1 fatigue after 1st session | 1st: PR 2nd: PR 3rd: CR. |
No progression. Second treatment 4 months later for residual disease, followed by the 3rd treatment for residual disease 5 months afterwards. | Negative for 15 months. | 15 months, alive, pending resection or transplant evaluation. |
| 4 | 1st: rRHA (113Gy) 2nd: rRHA (64Gy) |
1st: 9% 2nd: 11% |
G1 nausea in both sessions. G2 hyperbilirubinemia after 1st session | None | 1st: PR 2nd: PR. |
1st: Negative for 1 month until 2nd. 2nd: negative for 9 months. |
Enlargement of satellite lesions at 9 months. | Alive, 15 month. Enrolled in clinical trial. |
| 5 | Right hepatic artery (123Gy) | 8% | Myositis | None | CR | Negative for 8 months. | New lesions at 8 months. | Died, 10 months. |
| 6 | Segment 6 branch rRHA (315Gy) and LHA (252Gy) for 2 lesions. | 4.1% | None. | G1 ALP, hypoalbuminemia | CR for both lesions. | Negative for 8 months for both treated lesions. | Negative for 8 months. | Alive, 9 months. |
| 7 | Segmental ⅝ (200Gy) and 4 (200Gy) | 5.2% | None. | G1 leukopenia | PR | Negative for 13 months. | Negative for 13 months. | Alive, 16 months. |
| 8 | Segment ⅔, confluence lesion (150Gy) | 10.5% | G1 hyperbilirubinemia, alt. G3 AST elevation | G3 AST elevation. G2 ALT elevation, hypoalbuminemia. G1 ALP elevation | SD | Negative for 2 month | Positive, 2 month | Died, 4 months. |
| 9 | Segment 2 artery (408Gy) | 4.5% | None. | G1 hyperbilirubinemia | CR | Negative for 14 months. | Negative for 14 months. | Alive, 14 months. |
| 10 | rRHA (412 Gy) | 13% | G1 Fatigue and fever | NA | NA | NA | NA | Alive, 4 months. |